S. Both of the components of SOLX's DeepLight System have received CE approval from the European Agency for the Evaluation of Medicinal Products and are currently the subject of two randomized , multi-center studies in the United States. Mr. SOLX's DeepLight Glaucoma Treatment System is being developed to provide physicians with new tools to reduce intraocular pressure.

squint ophthalmoplegic

OccuLogix, Inc . William (Bill) G. Dumencu, CA, has been appointed as the company's interim Chief Financial Officer and Treasurer, effective April 10, 2006. Dumencu succeeds John Y. These statements are only predictions based on our current expectations and projections about future events. These cuts have
occurred, she said, despite the fact that cataract surgery is extremely cost-
effective, restores vision, significantly enhances the quality of life of
patients, and reduces morbidity and mortality.

eyesight uveitis

OccuLogix plans on meeting with the U. In light of the possible delay in the U.

About SOLX, Inc. We do not undertake to update any forward-looking statements. WASHINGTON, The American Society of Cataract and
Refractive Surgery (ASCRS) today warned that continuation of the trend of
reducing reimbursements to physicians for services provided under Medicare
could lead to a crisis in practice and eventually reduce patient access to
Medicare services."
Dr.

phpv microphthalmia

While the Company cannot predict what the FDA will require for approval, management believes that it is more likely than not that further study will be required due to the fact that the modified per-protocol population comprised 115 complete data sets while the Company had been required to obtain a minimum of 150 complete data sets. SOLX expects to obtain 510K approval to market both components of the DeepLight System in the United States before the end of 2007 ., has recently joined OccuLogix as Vice President, Clinical Research. "I'm also excited to welcome Drs .

deafblindness nystagmus

Together we will continue to focus our commitment and resources in changing the very paradigm by which physicians view and treat age-related eye diseases. Westing earned his Ph. Dumencu has served as OccuLogix's V. Currently, there is no FDA approved treatment for Dry AMD.7 million suffering from blindness. In the United States, approximately 2.

amblyopia phpv

org.org. The video news release of this story will be
distributed via satellite on:

Friday April 15th, 2005
1:00PM-1:15PM ET
IA 5
C-Band
Transponder 15
Downlink Freq: 4000 Vertical

Monday April 18th, 2005
1:30PM-1:45PM ET
IA 5
C-Band
Transponder 24
Downlink Freq: 4180 Horizontal

The American Society of Cataract and Refractive Surgery is an
international educational and scientific organization whose 9,000 member
ophthalmologists specialize in surgical procedures of the eye.

cataracts autonomic

Expanding OccuLogix's ophthalmic pipeline beyond the RHEO procedure for Dry AMD was already a longer-term corporate objective. Dr. She has served on several committees in the National Science and Engineering Research Committee of Canada and has an appointment at the University of Toronto as lecturer. In that role, Dr. There, he held increasingly senior roles in product sales and development.

There are two types of AMD - "dry", or non-exudative, and "wet", or exudative .rheo.

Based at the Boston University Photonics Center in Boston, Massachusetts, SOLX is a privately held company developing new approaches to glaucoma treatment. Arnold urged patients, physicians, and
policymakers to involve themselves in the debate on healthcare.

phpv microphthalmia

On March 9, 2006, OccuLogix announced positive results from the modified per-protocol analysis of MIRA-1, the Company's recently completed pivotal (phase III) clinical trial using its RHEO System to treat the dry form of age-related macular degeneration ("Dry AMD"). from May 1990. Dr. Choudry and Westing to the Company. Arnold noted that the Medicare
population is rising with the aging of the baby boom population.

ophthalmoplegic uveitis

Like our RHEO system, the DeepLight System has the potential to represent a significant benefit for patients, as well as a tremendous market opportunity for OccuLogix.
Using cataract surgery as her example, Dr.

eyesurgeryeducation.

floaters squint

D. Westing is joining OccuLogix from Genentech, Inc. in Muscle Physiology at The Karolinska Institute, Stockholm, Sweden.

About Glaucoma

Glaucoma is a group of age-related eye diseases characterized by elevated intraocular pressure, which cause optic nerve damage and subsequent loss of eyesight. At first, peripheral vision is lost.com. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities, including our Registration Statement on Form S-1. The Society publishes the peer-
reviewed Journal of Cataract and Refractive Surgery.

nystagmus irlen

S. The DeepLight Glaucoma Treatment System ("DeepLight System") includes the DeepLight 790 Titanium Sapphire Laser and the novel DeepLight Gold Micro-Shunt, which can be used separately or together to provide patients with multiple options for maximum intraocular pressure ("IOP") management . Caloz who will be leaving the company to pursue other opportunities. Highly skilled
ophthalmologists needed to care for patients with cataracts face a crisis in
practice and may simply not be there to provide the care in the future, said
outgoing ASCRS President Priscilla Arnold, MD.5 million today to 30.1 million by the year
2020.

amblyopia squint

(NASDAQ: RHEO)(TSX:RHE) today provided a strategic update and announced its planned acquisition of SOLX, Inc. Based at the world renowned Boston University Photonics Center , SOLX is a privately held company that has developed a next generation system that represents a paradigm shift in the way glaucoma is currently treated. Paralleling our own novel device approach to the treatment of age-related eye diseases, we believe that SOLX's product portfolio represents the perfect fit for OccuLogix's development and commercialization capabilities.

Nozhat Choudry, Ph. Choudry worked at Ciba-Geigy (now Novartis Corporation) where she held increasingly senior roles in drug development and clinical trial management.D.P. I look forward to their input as we work toward building a strong leadership position for OccuLogix within the ophthalmic device space.

Worldwide, it is estimated that approximately 67 million people have visual impairment from glaucoma, with 6. Visit us on the internet at www. You should not place undue reliance on these statements.

TV News Editors: See Satellite Coordinates below.

cornea ocular

commercial launch of its RHEO System, the Company has accelerated its diversification plans, focusing on age-related eye diseases like AMD and glaucoma as they are expected to be the fastest growing segments of eye care over the next 10 years., OccuLogix's Vice President, Clinical Affairs, who will be leaving the company to pursue other opportunities., has been appointed OccuLogix's Vice President, Medical and Scientific Development, effective April 10, 2006.

Mr.

Forward Looking Statements

This press release may contain forward-looking statements. "People of goodwill can solve this
looming problem.

lukes floaters

3 million by the year 2020

About OccuLogix, Inc.

conjunctivitis cornea

D. From March 1993 to August 1996, Dr. Choudry earned her Ph. Choudry will be assuming the responsibilities of Irving Siegel , M.

conjunctivitis microphthalmia

OccuLogix's Planned Acquisition of SOLX, Inc. Westing will be primarily responsible for identifying and developing relationships with key opinion leaders within ophthalmology, and for managing the recruitment of trial sites and patients to participate in OccuLogix sponsored clinical studies. The macula is responsible for our ability to see with enough detail to read, drive, watch television and perform other activities that require focused, straight-ahead vision, as well as providing information that allows us to perceive colors; thus, allowing one to maintain independence in daily activities. More information can be found online at www.

About ocular diseases and disorders with their treatment.

amblyopia nystagmus

Before joining Genentech in May 1996, Dr. If glaucoma is not treated, vision loss may continue, leading to total blindness over time.

deafblindness ophthalmoplegic

PRESS RELEASE OccuLogix Expands Focus on Age-Related Eye Diseases

OccuLogix has initiated its expansion into the glaucoma space by signing a Letter of Intent to acquire SOLX, Inc."

Doug Adams, SOLX's President and CEO, commented "SOLX and OccuLogix together will provide new hope for the patients suffering from these potentially blinding eye diseases. Dr.D. Mr. Finance since June 2005 and was previously OccuLogix's Chief Financial Officer and Treasurer from September 2003."

About AMD

Age-related macular degeneration causes damage to the macula - the light-sensitive cells at the center of the retina at the back of the eye.2 million people age 40 and older have glaucoma, and of these, as many as 120,000 are blind due the disease.

As a remedy for the problem , Dr. Arnold said. Arnold's comments came during ceremonies at the 31st Annual Symposium
of the ASCRS .

ophthalmoplegic hyperthyroid

of Boston, Massachusetts. Dr. Dr.

hyperthyroid eyesight

While financial terms of the transaction were not disclosed, OccuLogix will provide SOLX with a $2 million bridge loan and has advised that it expects substantially all of the purchase price of SOLX to be paid in OccuLogix stock. The total
number of people with cataracts (a vision-obstructing clouding of the eye's
lens) is expected to rise from 20.
ASCRS has prepared a brochure on the subject entitled, A Vision for the
Future: Delivering the Best in Cataract Care for You and Your Children, which
can be obtained by contacting ASCRS at JCiccone@ascrs. They
specialize in treating cataracts, glaucoma, diseases and trauma of the cornea,
and pediatric eye disorders, and in vision correction procedures using laser-
based and artificial lens technologies.

microphthalmia aniridia

Food and Drug Administration ("FDA") in the second quarter to discuss what impact the MIRA-1 study results and the modified per-protocol analysis will have on its application to market its RHEO System in the United States. Dr. in Clinical Pharmacology at the Royal Postgraduate Medical School in London, England and has done extensive post-graduate research and publishing in both pharmacology and medicine.D.

"I deeply appreciate all of the hard work and valuable insights that John Caloz and Irv Siegel provided and wish them both well in their future endeavors," said Vamvakas.0 to 13. "Physicians
must receive Medicare reimbursements that keep up with the cost of treating
Medicare beneficiaries," Dr.

eyesight ophthalmoplegic

Choudry has an accomplished history in global drug development and clinical trial management.

Steve Westing , Ph.
Between 1990 and 2005, Medicare reimbursement has been cut from $1,500 to
about $684 , a constant-dollar reduction of 71 percent.
For more information about cataract surgery go to
http://www. Arnold and two patients who
have had cataract surgery.

nearsighted autonomic

She joined OccuLogix from Boehringer Ingelheim, where she worked for the past 9 years, most recently as Director of the National Medicine Department.

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market.com (healthcare professionals, patients and caregivers). The Medicare reimbursement system must be replaced with one
that accurately reflects expense increases in medical practices . Cataracts occur primarily in seniors, and the surgery represents a
significant Medicare expenditure .

motility microphthalmia

Elias Vamvakas, OccuLogix's Chairman and CEO, commented "We're excited to be expanding our focus beyond Dry AMD by entering the fast-growing glaucoma space."

Management Changes

In connection with its new strategic direction, OccuLogix has made a number of structural and management changes designed to both support the continued development of its existing Dry AMD program and to execute on its accelerated diversification strategy within ophthalmology. (NYSE: DNA), where he most recently served as Associate Director - Advisory and Thought Leader Services. Dry AMD, the most common form of the disease, currently afflicts approximately 13. Actual events or results may differ materially.

The video features interview segments with Dr.

presbyopia squint

Westing helped establish the thought leader development program for Genentech 's newly launched Lucentis franchise and he served as a member of Genentech's ophthalmology commercial strategy team. Westing worked at Loredan Biomedical, Inc.5 million people in the United States, representing approximately 85% to 90% of all AMD cases in the country. The number of Americans with glaucoma is estimated to increase to 3. OccuLogix's common shares trade on the NASDAQ National Market under the symbol 'RHEO ' and on the Toronto Stock Exchange under the symbol 'RHE'.SOLX.

ASCRS Calls for Medicare Reimbursement System Reform That Accurately Reflects Cost Increases in Caring for Patients

There is very real evidence that newer technology may not become available
to senior citizens without adequate Medicare funding.

ocular nearsighted

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)